| 1 |
35006035 | Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. | 2022 Jan-Dec |
1 |
| 2 |
33776786 | PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting. | 2021 |
1 |
| 3 |
34718032 | Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. | 2021 Oct 28 |
1 |
| 4 |
34944024 | Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation. | 2021 Dec 13 |
1 |
| 5 |
32308016 | Vorapaxar in the treatment of cardiovascular diseases. | 2020 Sep |
1 |
| 6 |
33078834 | The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis. | 2020 Nov 13 |
1 |
| 7 |
30324870 | Oral antiplatelet agents in cardiovascular disease. | 2019 Jul |
1 |
| 8 |
31642690 | Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial. | 2019 Oct 23 |
1 |
| 9 |
33609100 | Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial. | 2019 Oct 23 |
1 |
| 10 |
28403576 | No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers. | 2018 Feb |
2 |
| 11 |
28565918 | Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. | 2018 Jan |
1 |
| 12 |
29864779 | Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia. | 2018 Jul |
2 |
| 13 |
30498684 | Diabetes and antiplatelet therapy: from bench to bedside. | 2018 Oct |
1 |
| 14 |
27489245 | Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us. | 2017 Mar |
2 |
| 15 |
28063023 | Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. | 2017 Mar |
1 |
| 16 |
28135897 | Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome. | 2017 Mar |
1 |
| 17 |
28148395 | Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. | 2017 Apr |
1 |
| 18 |
28981200 | Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy. | 2017 Dec |
1 |
| 19 |
26966273 | Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking. | 2016 May |
1 |
| 20 |
26984587 | Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. | 2016 |
1 |
| 21 |
27131284 | Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran. | 2016 Jun |
2 |
| 22 |
27261371 | Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy. | 2016 Dec |
2 |
| 23 |
27366081 | Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar. | 2016 |
1 |
| 24 |
27398626 | Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition. | 2016 Nov |
1 |
| 25 |
24750101 | PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. | 2015 |
3 |
| 26 |
25895464 | Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events. | 2015 May |
1 |
| 27 |
26022529 | In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist. | 2015 Sep 5 |
4 |
| 28 |
26338971 | Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. | 2015 Nov 17 |
1 |
| 29 |
26386102 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. | 2015 Oct 1 |
1 |
| 30 |
26406386 | Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. | 2015 Sep |
1 |
| 31 |
24676931 | PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. | 2014 Nov |
1 |
| 32 |
25525635 | Vorapaxar for the reduction of atherothrombotic events. | 2014 Nov |
1 |
| 33 |
26104312 | Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword! | 2014 |
1 |
| 34 |
23396280 | Efficacy and safety of vorapaxar in patients with prior ischemic stroke. | 2013 Mar |
1 |
| 35 |
23501976 | Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. | 2013 Apr 9 |
1 |
| 36 |
27121783 | Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers. | 2013 Jul |
2 |
| 37 |
21248619 | Protease-activated receptor-1 antagonists: focus on SCH 530348. | 2012 Nov |
1 |
| 38 |
22077816 | Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. | 2012 Jan 5 |
2 |
| 39 |
22443427 | Vorapaxar in the secondary prevention of atherothrombotic events. | 2012 Apr 12 |
1 |
| 40 |
22476387 | Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin. | 2012 Nov |
1 |
| 41 |
22932716 | Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. | 2012 Oct 13 |
1 |
| 42 |
20307225 | Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348. | 2010 Apr |
2 |
| 43 |
20836572 | Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. | 2010 Oct 1 |
1 |
| 44 |
19699853 | The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. | 2009 Sep |
1 |
| 45 |
19699854 | Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. | 2009 Sep |
1 |
| 46 |
19705342 | SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. | 2009 Sep |
1 |
| 47 |
19715408 | SCH 530348: a novel oral thrombin receptor antagonist. | 2009 Sep |
3 |
| 48 |
19882073 | Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. | 2009 Nov |
3 |
| 49 |
18574020 | New antiplatelet therapies in development. | 2008 Jul 1 |
1 |